Moreover, a previous study showed that in non-small-cell lung cancer, demethylation of the FOXP3 gene promoter could reduce the activity of DNMTs in Tregs CD4+ lymphocytes and downregulate immune responses in the TME (Ke et al., 2016). Here, FOXP3 is linked to non-small cell lung carcinoma.